Freund John Gordon

Average Profitability
17.82%
Insider Buys Quantity
3
Insider Buys Sum
$15.35M
Insider Sells Quantity
27
Insider Sells Sum
$83.51M

Insider Activity of Freund John Gordon

The largest purchase of all time was on 2018-10-19 and amounted to 650000 shares of SI-BONE, Inc. for $9.75M.

The largest sale of all time was on 2021-03-17 and amounted to 666200 shares of SI-BONE, Inc. for $20.24M.

Biography of Freund John Gordon

No biography is available at this moment.

2023-08-09SaleSI-BONE, Inc.
SIBN
director
30,000
0.0769%
$20.54$616,197-12.95%
2021-06-16SaleSI-BONE, Inc.
SIBN
director
12,591
0.0377%
$31.41$395,427-32.1%
2021-06-15SaleSI-BONE, Inc.
SIBN
director
21,511
0.0654%
$31.11$669,136-30.3%
2021-06-14SaleSI-BONE, Inc.
SIBN
director
17,990
0.0545%
$31.28$562,738-30.89%
2021-05-28SaleSI-BONE, Inc.
SIBN
director
45,220
0.1366%
$30.06$1.36M-27.66%
2021-05-27SaleSI-BONE, Inc.
SIBN
director
26,367
0.0799%
$30.93$815,523-29.44%
2021-05-26SaleSI-BONE, Inc.
SIBN
director
17,138
0.052%
$31.85$545,833-31.35%
2021-05-25SaleSI-BONE, Inc.
SIBN
director
1,696
0.0053%
$32.55$55,197-31.5%
2021-05-24SaleSI-BONE, Inc.
SIBN
director
51,027
0.1548%
$32.54$1.66M-32.74%
2021-03-17SaleSI-BONE, Inc.
SIBN
director
666,200
1.9363%
$30.39$20.24M-28.55%
2021-03-16SaleSI-BONE, Inc.
SIBN
director
55,053
0.1678%
$30.33$1.67M-24.89%
2021-03-15SaleSI-BONE, Inc.
SIBN
director
80,887
0.2461%
$30.90$2.5M-26.36%
2021-03-12SaleSI-BONE, Inc.
SIBN
director
91,072
0.2786%
$31.39$2.86M-26.6%
2021-03-11SaleSI-BONE, Inc.
SIBN
director
63,928
0.1943%
$31.05$1.98M-26.24%
2020-12-03SaleSI-BONE, Inc.
SIBN
director
47,886
0.1515%
$23.39$1.12M+27.14%
2020-12-02SaleSI-BONE, Inc.
SIBN
director
100,000
0.3158%
$23.28$2.33M+27.52%
2020-10-19SaleSI-BONE, Inc.
SIBN
190,053
0.573%
$22.00$4.18M+28.85%
2020-09-18SaleSutro Biopharma, Inc.
STRO
director
800,000
2.1944%
$12.00$9.6M+65.94%
2020-09-11SaleSutro Biopharma, Inc.
STRO
director
1M
2.6591%
$10.00$10M+89.12%
2020-08-19SaleSutro Biopharma, Inc.
STRO
director
1M
2.5584%
$8.72$8.72M+102.44%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.